Roche turns up the heat on Lil­ly with an­oth­er Gavre­to ap­proval, el­bow­ing its way in­to the thy­roid can­cer space

Roche and Blue­print Med­i­cines are con­tin­u­ing to put pres­sure on ri­vals Eli Lil­ly and Loxo, as their Gavre­to drug picked up a new ap­proval Wednes­day.

The com­pa­nies an­nounced that the FDA has giv­en the thumbs-up for Gavre­to to treat RET-mu­ta­tion and RET-fu­sion pos­i­tive thy­roid can­cers, less than three months af­ter the drug re­ceived its first ap­proval in non-small cell lung can­cer with RET fu­sions. Gavre­to is now set to ful­ly com­pete with Lil­ly’s Retev­mo af­ter the lat­ter’s brief pe­ri­od as the on­ly de­vel­op­er with an OK’ed med­i­cine for this spe­cif­ic gene al­ter­ation.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER